Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 31st total of 1,860,000 shares. Approximately 12.9% of the shares of the company are short sold. Based on an average daily trading volume, of 768,100 shares, the short-interest ratio is presently 3.3 days.
Aerovate Therapeutics Price Performance
Shares of NASDAQ AVTE opened at $2.58 on Thursday. The firm has a market capitalization of $74.51 million, a PE ratio of -0.86 and a beta of 1.00. Aerovate Therapeutics has a 1-year low of $1.25 and a 1-year high of $32.42. The business’s fifty day moving average price is $2.60 and its two-hundred day moving average price is $2.25.
Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.03. Equities research analysts expect that Aerovate Therapeutics will post -2.64 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aerovate Therapeutics
About Aerovate Therapeutics
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Further Reading
- Five stocks we like better than Aerovate Therapeutics
- How to Capture the Benefits of Dividend Increases
- ASML: Strengths and Upside Remain Despite DeepSeek Worries
- What Are Dividend Achievers? An Introduction
- Royal Caribbean Soars, But Smooth Sailing Isn’t Guaranteed
- Stock Sentiment Analysis: How it Works
- Kimberly-Clark: A Regal Opportunity in This Dividend King
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.